Drug intelligence / Profile preview

Cystus

Development stage: Unknown
Lead developer: Bioithas
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bioithas Cystus is a probiotic-based dietary supplement specifically formulated to support urinary tract health and manage recurrent urinary tract infections (UTIs). Developed by the Spanish company Bioithas, the supplement combines specific live probiotic strains (1x10^9 CFU) with American red cranberry extract (providing 120 mg of proanthocyanidins) and Vitamin C (16 mg). The mechanism of action involves the modulation of the urinary and vaginal microbiota to inhibit the colonization of pathogenic bacteria and improve overall urinary comfort. It is administered orally in capsule form and is marketed as a food supplement rather than a traditional pharmaceutical drug.

Brand names: CystusBioithas Cystus
Other names: Bioithas Cystus probiotic supplement

Beyond the preview

Go deeper on Cystus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cystus.

Explore the full profile